Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib

H. Horinouchi, B.C. Cho, D.R. Camidge, Kōichi Goto, P. Tomasini, Y. Li, Athanasios Vasilopoulos, Priya Brunsdon, D. Hoffman, Wenyin Shi, Ellen Bolotin, Vincent Blot, Jonathan W. Goldman